论文信息 - Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective review - 字舞流文

Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective review

R. Vleugels | V. Nambudiri | K. Lo | S. Desai | A. Lachance | Camila Villa-Ruiz

[1] Nawaf Almutairi,et al. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study , 2018, Dermatology.

[2] A. Christiano,et al. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. , 2018, The Journal of investigative dermatology.

[3] J. Shapiro,et al. Alopecia areata , 2017, Nature Reviews Disease Primers.

[4] J. Ko,et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. , 2016, JCI insight.

[5] Amos Etzioni,et al. Alopecia areata. , 2012, The New England journal of medicine.

[6] J. M. Weitzner. Alopecia areata. , 1990, American family physician.